ArticleDiscover oncology2025
Evaluating the prognosis of prostate cancer through metabolic pathways.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Gene Feature Based on Histone Modifications Can Predict the Prognosis of Prostate Cancer.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe pathogenesis of prostate cancer (PCa) is strongly influenced by metabolism. Thus, we explored candidate genes with metabolism-related functions that can be used to predict PCa prognosis.
methodsTo create a training set and two validation sets, RNA data and clinical parameters were downloaded from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). Risk score (RS) was constructed based on metabolism-related gene signatures. The predictive power of the RS was evaluated. A nomogram related to biochemical recurrence-free survival (BCRFS) was built and evaluated. Finally, an enrichment analysis using Gene Set Enrichment Analysis (GSEA) was performed to identify enriched Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) categories. The Human Protein Atlas (HPA) platform was employed to identify the expression of important genes at the protein level.
resultsFive gene signatures from 860 metabolism-related genes were selected. RS were constructed using the five-gene signatures, which showed high prognostic power for biochemical recurrence (BCR). The nomogram effectively predicted BCRFS. According to GO analysis, DNA damage is primarily associated with genes involved in metabolism. The five-gene signatures were primarily enriched in sulfur metabolic pathways, as analyzed by KEGG. With the progression of prostate cancer malignancy, the expression of HAGHL, and INPP5E also increased.
conclusionThe study establishes a robust, metabolism-based prognostic model for prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.